

Datasheet for 600-101-096

Fluorescein (FITC) Antibody**Overview**

Description:	Anti-Fluorescein (GOAT) Antibody - 600-101-096
Item No.:	600-101-096
Size:	1 mg
Applications:	ELISA, WB, FISH, Microarray
Reactivity:	Fluorescein
Host Species:	Goat

Product Details

Background:	Anti-Fluorescein Antibody is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. Anti-FITC is also suitable as a visualization reagent for fluorescein-labelled compounds (such as antibodies, lectins and peptide nucleic acid (PNA) probes).
Synonyms:	goat Anti FITC, goat anti Fluorescein
Host Species:	Goat
Clonality:	Polyclonal
Format:	IgG

Target Details

Reactivity:	Fluorescein
Immunogen Type:	Other
Immunogen:	Fluorescein conjugated to Goat IgG
Purity/Specificity:	Fluorescein Antibody was prepared from monospecific antiserum by immunoaffinity chromatography using Fluorescein conjugated Goat IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Goat Serum and Fluorescein conjugated Bovine Serum Albumin.

Application Details

Tested Applications:	ELISA, WB
Suggested Applications:	FISH, Microarray (Based on references)
Application Note:	Anti-Fluorescein Antibody has been tested by ELISA and western blot and is suitable for immunomicroscopy, in situ hybridization and flow cytometry or FACS analysis as well as other antibody based fluorescent assays requiring lot-to-lot consistency.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:5,000 - 1:25,000
FC:	User Optimized
IHC:	1:250 - 1:1,500
WB:	1:500 - 1:3,000
Other:	FISH and in situ hybrid


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1.2mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling


Shipping Condition:	Wet Ice
Storage Condition:	Store vial at 4° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images


**Dot Blot**

Strong responses to polyclonal anti-HA antiserum are readily observable on an AIR hemagglutinin microarray. (a) 1% BSA control (p/n BSA-10). (b) Anti-H7 polyclonal antiserum (A/Netherlands/219/2003, H7N7), 1:80 dilution (1.3%) in 1% BSA. Spots showing substantially increased brightness indicate binding to immobilized H7. In both cases, antigens were arrayed in square patterns as indicated by the yellow boxes in (a); a mouse IgG Fc domain (p/n 010-0103) was included as negative control (red boxes). Slight differences in spot intensity in the control (a) are due to differences in deposition efficiency for different antigens or controls. Specific antigens used in these experiments are indicated in Table 2. Goat anti-fluorescein, (p/n 600-101-096) used as an internal negative control.

Fig 1. PMID: 26241048.


**Fluorescence in situ Hybridization (FISH)**

Self-cleaving ribozymes can tune gene expression in *Drosophila* embryos. (B-E) Representative images of in situ hybridized *Drosophila* embryos probed for lacZ. Each embryo imaged expresses lacZ under the control of the hbpe and contains an inactive (B/D) or active (C/E) ribozyme. Red triangles represent the width of the lacZ gradient. Fig 3. PMID: 32352996.




Fluorescence in situ Hybridization (FISH)

L–M. Squamous cell carcinoma from mouse 1; P–S. Breast cancer from mouse 4. L–M Squamous cell carcinoma from mouse 1. The squamous cell carcinoma in the breast of mouse 1 does not contain Y-Chromosomes, whereas the breast adenocarcinoma in mouse 4 (E–F) does. L. DAPI (nuclei), M. in situ for Y-chromosome (40X). The arrows mark the border between the squamous cell carcinoma and the stroma. P–S. Breast Cancer from mouse 4. P. DAPI showing nuclei in the tumor. Q. In situ for Y-chromosomes (20X) showing up to 80% of nuclei in tumor contain Y-chromosome in this section. The arrows in O–Q delineate the border of the stroma and the tumor. In contrast to M, Q shows that the tumor labels strongly for Y-chromosomes, whereas the stroma is weakly labeled. S in situ for Y-chromosome of breast adenocarcinoma (40X). The larger arrow shows a focus of cancer in the H&E section that is labeled for Y-chromosome in a serial section. Figure 1. PMID: 19816927.




Fluorescence in situ Hybridization (FISH)

A–D. Y-chromosome labeling of control and experimental lesions. A. Male liver. Note high labeling of hepatocytes (70%). This is the expected frequency as some Y-chromosomes are not in the plane of the tissue section. B. Liver from female recipient of male bone marrow. Hepatocytes are not labeled, but many endothelial cells and Kupffer cells are. C, D Lung adenocarcinoma. C. DAPI; D. FISH. The tumor cells do label for Y-chromosomes, whereas the stromal cells are heavily labeled. The arrows show the demarcation between the tumor and the stroma. Fig 2. PMID: 19816927.




Western Blot

CB2R agonist JWH133 prevents bleomycin-induced collagen I expression in mice lung tissue. (A) The expression of cannabinoid receptor type 2 (CB2R), collagen I (Col1a1) and α-SMA (Acta2) were evaluated by western blotting. Figure 5. PMID: 29262578 .



Figure

Assay precision and selectivity. (a) Fraction of intra-assay data points that are within 20% CV for trials in BSA and serum backgrounds for IL-17A (left) and CRP (right) as a function of negative control subtraction. The cutoff of 0.65 is indicated with a red dashed line. (b) Fraction of interassay data points that are within 20% CV for trials in BSA and serum backgrounds for IL-17A (left) and CRP (right) as a function of negative control subtraction. The cutoff of 0.65 is indicated with a red dashed line. (c) Measured concentrations corresponding to the limits of detection (LOD) and lower limit of quantitation (LLOQ) as a function of negative control protein for both IL-17A and CRP across several trials conducted in either 1% BSA or serum. LOD = LOB + 1.645σ. Abbreviations: FBS-D: FBS-containing diluent. Fig 5. PMID: 39898999



Western Blot

Western Blot of Goat Anti-Fluorescein Antibody. Lane 1: Opal Prestained Molecular Weight Marker (p/n MB-210-0500). Lane 2: Bovine Albumin (BSA) (p/n 001-0133) [0.05μg]. Lane 3: Bovine Albumin-Fluorescein (BSA-FITC) (p/n 001-0233) [0.05μg]. Primary Antibody: Gt-anti-Fluorescein 1.0μg/mL overnight at 2-8°C. Secondary Antibody: Donkey Anti-Goat HRP (p/n 605-703-002) at 1:40,000 for 30mins at RT. Block: 5% BLOTTO (p/n B501-0500) in 1X PBS for 1hr at RT. Predicted MW: ~60kDa. Observed MW: ~65kDa. Exposure: 1sec.

References

- Klose AM et al. Dual-Scale StaphAIR: Predictive Modeling for the Diagnosis of *S. aureus* Infection via Simultaneous Detection and Quantification of Cytokines and Antibodies. *Anal Chem.* (2026)
- Klose AM et al. Lambda Theta Reflectometry: A New Technique for Measuring Optical Film Thickness in Planar Protein Arrays. *ACS Sens.* (2025)
- Butt JN et al. A Dual-Readout Photonic Sensor for Simultaneous Measurement of Enzyme Activity and Concentration. *ACS Sens.* (2025)
- Bucukovski J et al. Everything's under Control: Maximizing Biosensor Performance through Negative Control Probe Selection. *Anal Chem.* (2025)
- John S Cognetti et al. Disposable photonics for cost-effective clinical bioassays: application to COVID-19 antibody testing. *Lab Chip.* (2021)
- Asafen HA et al. Robustness of the Dorsal morphogen gradient with respect to morphogen dosage. *PLoS Comput Biol.* (2020)
- Jacobsen T et al. Tunable self-cleaving ribozymes for modulating gene expression in eukaryotic systems. *PLoS One* (2020)
- Liu et al. Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice. *International Journal of Molecular Medicine* (2017)
- Fu et al. Activation of cannabinoid receptor type 2 by JWH133 alleviates bleomycin-induced pulmonary fibrosis in mice. *Oncotarget* (2017)
- Bucukovski, J et al. A Multiplex Label-Free Approach to Avian Influenza Surveillance and Serology. *PLoS One* (2015)
- Guest et al. Survival of irradiated recipient mice after transplantation of bone marrow from young, old and "early aging" mice. *Aging* (2015)
- Guest I et al. Direct and indirect contribution of bone marrow-derived cells to cancer. *Int J Cancer.* (2010)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.